AAPL 168.0 -0.8147% MSFT 411.84 -0.6609% GOOG 156.88 0.5641% GOOGL 155.47 0.693% AMZN 181.28 -1.1128% NVDA 840.35 -3.8666% META 494.17 -1.1185% TSLA 155.45 -1.0566% TSM 139.03 -0.5508% LLY 750.77 0.5397% V 272.69 0.4938% AVGO 1282.63 -3.4934% JPM 180.08 -0.3982% UNH 478.99 2.154% NVO 124.53 0.8748% WMT 59.65 -0.3175% LVMUY 170.745 -0.914% XOM 118.65 -0.0337% LVMHF 858.0 0.345% MA 460.16 0.0739%
Last update at 2024-04-17T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -71.03800M | -6.55300M | -155.63600M | -86.37200M | -59.97800M |
| Minority interest | - | - | - | - | - |
| Net income | -63.42200M | -10.80400M | -159.63100M | -89.93500M | -57.69200M |
| Selling general administrative | 32.22M | 31.88M | 22.86M | 22.12M | 18.79M |
| Selling and marketing expenses | 39.92M | 35.19M | 26.61M | 24.49M | 4.94M |
| Gross profit | 46.95M | 39.12M | 15.32M | 1.90M | 1.52M |
| Reconciled depreciation | 2.11M | 2.42M | 2.77M | 2.53M | 2.29M |
| Ebit | -78.65400M | -78.03700M | -62.84700M | -85.80200M | -59.11800M |
| Ebitda | -77.85700M | -78.00300M | -62.67900M | -84.58100M | -58.23900M |
| Depreciation and amortization | 0.80M | 0.03M | 0.17M | 1.22M | 0.88M |
| Non operating income net other | 14.64M | 78.16M | -86.02100M | 5.53M | 0.88M |
| Operating income | -78.65400M | -78.03700M | -62.84700M | -85.80200M | -59.11800M |
| Other operating expenses | 130.15M | 121.56M | 80.25M | 90.03M | 61.11M |
| Interest expense | 7.02M | 6.67M | 6.77M | 6.10M | 1.74M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.80M | 0.03M | 0.17M | 1.23M | 0.88M |
| Net interest income | -6.22400M | -6.63800M | -6.60000M | -4.87200M | -0.86000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -7.61600M | 4.25M | 4.00M | 3.56M | -2.28600M |
| Total revenue | 51.49M | 43.52M | 17.40M | 4.23M | 1.99M |
| Total operating expenses | 125.61M | 117.15M | 78.17M | 87.70M | 60.64M |
| Cost of revenue | 4.54M | 4.41M | 2.08M | 2.33M | 0.47M |
| Total other income expense net | 7.62M | 71.48M | -92.78900M | -0.57000M | -0.86000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -71.03800M | -6.55300M | -155.63600M | -86.37200M | -59.97800M |
| Net income applicable to common shares | -71.03800M | -6.55300M | -155.63600M | -86.37200M | -59.97800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 149.29M | 204.89M | 261.86M | 78.74M | 73.04M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.03M | 4.75M | 4.65M | 2.23M | 1.71M |
| Total liab | 113.91M | 116.89M | 185.77M | 82.37M | 37.17M |
| Total stockholder equity | 35.38M | 88.00M | 76.09M | -3.63000M | 35.88M |
| Deferred long term liab | 6.35M | 20.19M | 98.31M | 12.12M | 3.22M |
| Other current liab | 24.10M | 7.12M | 2.31M | 7.63M | 6.19M |
| Common stock | 0.00800M | 0.00800M | 0.00800M | 0.00500M | 0.00400M |
| Capital stock | 0.00800M | 0.00800M | 0.00800M | 0.00500M | 0.00400M |
| Retained earnings | -616.84200M | -545.80400M | -539.25100M | -383.61500M | -297.24300M |
| Other liab | 19.83M | 33.19M | 110.31M | 12.12M | 3.22M |
| Good will | - | - | - | - | - |
| Other assets | 1.76M | 1.76M | 7.61M | 1.76M | 6.61M |
| Cash | 102.30M | 164.16M | 228.06M | 54.44M | 54.06M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 31.39M | 26.34M | 26.66M | 12.03M | 9.16M |
| Current deferred revenue | 0.58M | 13.00M | 12.00M | - | - |
| Net debt | -38.01700M | -105.18100M | -169.61800M | 4.91M | -29.27400M |
| Short term debt | 1.60M | 1.62M | 9.65M | 1.13M | - |
| Short long term debt | - | - | 8.29M | - | - |
| Short long term debt total | 64.28M | 58.98M | 58.44M | 59.34M | 24.79M |
| Other stockholder equity | 652.21M | 633.79M | 615.34M | 379.98M | 333.11M |
| Property plant equipment | 9.86M | 11.82M | 8.10M | 10.15M | 10.24M |
| Total current assets | 129.63M | 191.30M | 246.16M | 60.17M | 56.19M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 35.38M | 88.00M | 76.09M | -3.63000M | 35.88M |
| Short term investments | - | - | - | - | - |
| Net receivables | 21.32M | 21.14M | 12.25M | 2.55M | 0.20M |
| Long term debt | 54.01M | 51.44M | 41.24M | 49.31M | 24.79M |
| Inventory | 1.97M | 1.25M | 1.20M | 0.95M | 0.22M |
| Accounts payable | 5.12M | 4.59M | 2.71M | 3.27M | 2.96M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -10.01900M | -7.62700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.00800M | 0.00800M | 0.00800M | 0.00500M | 0.00400M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -616.84200M | -545.80400M | -539.25100M | -383.61500M | -297.24300M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.76M | 1.76M | 1.76M | 1.76M | 6.61M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 19.66M | 13.59M | 15.70M | 18.57M | 16.85M |
| Capital lease obligations | 10.28M | 7.55M | 8.91M | 10.03M | - |
| Long term debt total | 54.01M | 51.44M | 41.24M | 49.31M | 24.79M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -3.71500M | -1.19400M | -0.84100M | -2.23800M | -1.88900M |
| Change to liabilities | 1.02M | 2.80M | 1.86M | 1.84M | 0.92M |
| Total cashflows from investing activities | -3.71500M | -1.19400M | -0.84100M | -2.23800M | -1.88900M |
| Net borrowings | - | -0.44500M | -0.44500M | 37.27M | 6.38M |
| Total cash from financing activities | 1.45M | 2.85M | 228.01M | 75.34M | 68.64M |
| Change to operating activities | 1.92M | 3.23M | -0.42200M | 1.08M | 1.45M |
| Net income | -71.03800M | -6.55300M | -155.63600M | -86.37200M | -59.97800M |
| Change in cash | -61.86400M | -63.89300M | 173.62M | -4.47500M | 17.52M |
| Begin period cash flow | 165.93M | 229.82M | 56.20M | 60.68M | 43.15M |
| End period cash flow | 104.06M | 165.93M | 229.82M | 56.20M | 60.68M |
| Total cash from operating activities | -59.60300M | -65.55000M | -53.55400M | -77.57800M | -49.22700M |
| Issuance of capital stock | 0.00000M | 0.00000M | 224.68M | 37.54M | 61.57M |
| Depreciation | 2.11M | 2.42M | 2.77M | 2.53M | 2.29M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | 0.71M | 0.75M | - | 0.30M |
| Change to inventory | -0.72400M | -0.04900M | -0.24700M | -0.73700M | -0.09500M |
| Change to account receivables | -0.19000M | -8.88300M | -9.70400M | -2.34700M | 0.03M |
| Sale purchase of stock | 0.94M | 0.98M | 0.75M | 0.45M | 0.30M |
| Other cashflows from financing activities | -3.71500M | 7.02M | 6.53M | 37.35M | 12.73M |
| Change to netincome | 3.12M | -58.51700M | 93.72M | 4.46M | 7.48M |
| Capital expenditures | 3.71M | 1.19M | 0.84M | 2.24M | 1.89M |
| Change receivables | -0.19000M | -8.88300M | -9.70400M | -2.34700M | 0.03M |
| Cash flows other operating | 1.24M | 0.52M | 9.27M | -0.62900M | -0.26000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -61.86400M | -63.89300M | 173.62M | -4.47500M | 17.52M |
| Change in working capital | 1.35M | -2.90100M | 1.18M | -1.87500M | 0.58M |
| Stock based compensation | 16.96M | 14.98M | 7.53M | 8.76M | 7.48M |
| Other non cash items | -8.98700M | 4.63M | 4.41M | 3.68M | 0.40M |
| Free cash flow | -63.31800M | -66.74400M | -54.39500M | -79.81600M | -51.11600M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix Inc |
-0.21 2.70% | 7.58 | - | - | 8.19 | 57.18 | 7.30 | -7.5933 |
| NVO Novo Nordisk A/S |
1.08 0.87% | 124.53 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.41 1.15% | 124.15 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.07 0.27% | 393.10 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
0.13 0.15% | 87.96 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
24 Crosby Drive, Bedford, MA, United States, 01730
| Name | Title | Year Born |
|---|---|---|
| Mr. Antony Mattessich | Pres, CEO & Director | 1967 |
| Mr. Donald Notman Jr. | Chief Financial Officer | NA |
| Dr. Peter K. Jarrett Ph.D. | Chief Scientific Officer | 1957 |
| Mr. Philip C. Strassburger | Gen. Counsel | 1960 |
| Mr. William H. Ransone II | VP of Global Sales & Marketing | NA |
| Ms. Tracy Smith | VP of HR | NA |
| Mr. Scott Corning | Sr. VP of Commercial | NA |
| Mr. Christopher G. White | Chief Bus. Officer | 1962 |
| Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer | 1968 |
| Dr. Karen-Leigh Edwards M.B.A., Ph.D. | Sr. VP of Technical Operations | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...